ALLO-647

Overview

ALLO-647 is an anti-CD52 monoclonal antibody which is designed to be part of the lymphodepletion regimen. ALLO-647 may reduce the likelihood of a patient’s immune system rejecting the engineered allogeneic T cells, and may create a window of persistence during which the engineered allogeneic T cells can actively target and destroy cancer cells.

SparkCures ID 359
Developed By Allogene Therapeutics
Generic Name ALLO-647
Treatment Classifications
Treatment Targets
  • CD52

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.